Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CARMIEL, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today held an Analyst Event in which included the disclosure of new data regarding three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency.
Help employers find you! Check out all the jobs and post your resume.
